Olaparib is the first cancer drug to target inherited genetic mutations . one 30 per cent of men with advanced prostate cancer have tumours with genetic defects - and they responded well to olaparib . Drug prolongs time a sufferer can live without disease getting worse .
Olaparib is the first cancer drug to target inherited genetic mutations . Up to 30 per cent of men with advanced prostate cancer have tumours with genetic defects - and they responded well to olaparib . Drug prolongs time a sufferer can live without disease getting worse .